ARRAY BIOPHARMA INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $66.4M | $33.3M | $43.0M | $51.9M | $42.1M | $69.6M |
| Operating income | −$129.9M | −$102.1M | −$82.2M | $3.3M | −$75.6M | −$39.5M |
| Net income | −$22.9M | −$35.3M | −$22.7M | $9.4M | −$85.3M | −$61.9M |
| Total assets | $460.4M | $279.1M | $168.9M | $198.2M | $136.6M | $136.0M |
| Total liabilities | $240.6M | $267.4M | $206.8M | $155.6M | $162.3M | $157.9M |
| Equity | $219.7M | $11.7M | −$37.9M | $42.7M | −$25.7M | −$21.9M |
| EPS (diluted) | $-0.11 | $-0.21 | $-0.16 | $0.07 | $-0.69 | $-0.57 |
| Shares out. | 211.7M | 171.4M | 145.0M | 142.2M | 131.8M | 117.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −195.8%
- Net margin
- −34.4%
- Return on equity
- −10.4%
- Return on assets
- −5.0%
- Return on capital (ROCE)
- −35.7%
- Liabilities / assets
- 52.3%
- Debt / equity
- 1.10×
- Book value / share
- $1.04
- Revenue growth (YoY)
- 99.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -3.42distress
- Accruals / assets
- 21.1%high accruals
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Van Lunsen Gil JDirector | Jul 30, 2019 | D | 24,297 | $48.00 |
| Squarer RonOfficer — CEO | Jul 30, 2019 | D | 259,891 | $48.00 |
| Sharp ShaliniDirector | Jul 30, 2019 | D | 5,000 | $48.00 |
| Sandor VictorOfficer — Chief Medical Officer | Jul 30, 2019 | D | 209,543 | $48.00 |
| Saccomano Nicholas AOfficer — CSO | Jul 30, 2019 | D | 150,190 | $48.00 |
| Robbins Andrew ROfficer — COO | Jul 30, 2019 | D | 71,022 | $48.00 |
| Orwin John ADirector | Jul 30, 2019 | D | 15,000 | $48.00 |
| Lefkoff KyleDirector | Jul 30, 2019 | U | 22,635 | $48.00 |
| Haddock JasonOfficer — CFO | Jul 30, 2019 | D | 30,059 | $48.00 |
| Fyfe Gwen A.Director | Jul 30, 2019 | D | 15,000 | $48.00 |
| Cox Carrie SmithDirector | Jul 30, 2019 | D | 8,000 | $48.00 |
| Baum Charles MDirector | Jul 30, 2019 | U | 15,000 | $48.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJul 30, 2019
- Entered a material agreement · Director / officer change · Amended charter or bylaws · Other material eventJun 17, 2019
- Regulation FD disclosureMay 21, 2019
- Results of operationsMay 7, 2019
- Director / officer changeMar 22, 2019
- Regulation FD disclosureMar 18, 2019
- Director / officer changeFeb 20, 2019
- Results of operations · Regulation FD disclosureFeb 5, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.